Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen report data showing ‘clinical remission’ with Enbrel

Amgen report data showing ‘clinical remission’ with Enbrel

8th November 2007

Amgen and Wyeth Pharmaceuticals have reported new data showing that half of patients with active early rheumatoid arthritis achieved clinical remission after one year when treated with Enbrel (etanercept) plus Methotrexate.

This was in contrast to only 28 per cent achieving clinical remission when treated with methotrexate alone.

Study data from the multi-centre, randomised, double-blind trial Comet will be presented at the American College of Rheumatology Scientific Meeting in Boston this week.

The Comet trial marks the first major rheumatoid arthritis (RA) study with Enbrel which uses clinical remission as a primary endpoint.

It is measured with the disease activity score (DAS28) which looks at swelling and tenderness in 28 joints as well as overall disease activity.

Paul Emery, professor of rheumatology at the University of Leeds, confirmed that clinical remission was an important goal in clinical practice and particularly relevant to patients’ daily lives.

“We hope that both patients and physicians are encouraged by these findings as they set a new standard for earlier treatment of RA.”

Last month, Amgen announced that Aranesp (darbepoetin alfa) had been approved for use in paediatric patients suffering from chronic renal failure, irrespective of whether or not they are on dialysis.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.